clinical trial · NCT05970289
Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
Chronic Hepatitis B Virus InfectionPEG-IFNαBRII-835
brief summary
This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.
started
Aug 22, 2023
primary completion
Jul 16, 2025
completion
Feb 1, 2026
last updated
Sep 5, 2025
official title
A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol